Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabrina Arena

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Cancer Letters|July 4, 2024
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapyElena Richiardone, Rim Al Roumi, Fanny Lardinois, et al.
Molecular Cancer Therapeutics|October 11, 2013
BRAF V600E is a determinant of sensitivity to proteasome inhibitorsDavide Zecchin, Valentina Boscaro, Enzo Medico, et al.
Cell Death & Disease|February 9, 2023
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)Marta Falcinelli, Giulia Dell'Omo, Elena Grassi, et al.
Targeted Oncology|April 13, 2010
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancerAndrea Sartore-Bianchi, Katia Bencardino, Federica Di Nicolantonio, et al.
Cancer Letters|February 3, 2025
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancersElena Richiardone, Maria Virginia Giolito, Rim Al Roumi, et al.
Science Translational Medicine|February 28, 2020
High-dose vitamin C enhances cancer immunotherapyAlessandro Magrì, Giovanni Germano, Annalisa Lorenzato, et al.
Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
Frontiers in Oncology|February 23, 2023
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patientErica Torchiaro, Consalvo Petti, Sabrina Arena, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2008
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesFederica Di Nicolantonio, Sabrina Arena, Margherita Gallicchio, et al.
Cancers|March 19, 2020
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal CancerAnnalisa Lorenzato, Alessandro Magrì, Vittoria Matafora, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Cancer Letters|July 4, 2024
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapyElena Richiardone, Rim Al Roumi, Fanny Lardinois, et al.
Molecular Cancer Therapeutics|October 11, 2013
BRAF V600E is a determinant of sensitivity to proteasome inhibitorsDavide Zecchin, Valentina Boscaro, Enzo Medico, et al.
Cell Death & Disease|February 9, 2023
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)Marta Falcinelli, Giulia Dell'Omo, Elena Grassi, et al.
Targeted Oncology|April 13, 2010
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancerAndrea Sartore-Bianchi, Katia Bencardino, Federica Di Nicolantonio, et al.
Cancer Letters|February 3, 2025
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancersElena Richiardone, Maria Virginia Giolito, Rim Al Roumi, et al.
Science Translational Medicine|February 28, 2020
High-dose vitamin C enhances cancer immunotherapyAlessandro Magrì, Giovanni Germano, Annalisa Lorenzato, et al.
Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
Frontiers in Oncology|February 23, 2023
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patientErica Torchiaro, Consalvo Petti, Sabrina Arena, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2008
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesFederica Di Nicolantonio, Sabrina Arena, Margherita Gallicchio, et al.
Cancers|March 19, 2020
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal CancerAnnalisa Lorenzato, Alessandro Magrì, Vittoria Matafora, et al.
Pageof 6